LakeShore Biopharma Co (FRA:H6Z0) Cash Flow for Dividends: €0.00 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H6Z0 LakeShore Biopharma Co Ltd FRA:H6Z0
17 GF Score
Price €0.67
View Full Analysis

What is LakeShore Biopharma Co Cash Flow for Dividends?

LakeShore Biopharma Co FRA:H6Z0 17 Cash Flow for Dividends is €0.00 Mil as of Mar. 2025. GuruFocus rates FRA:H6Z0 with a GF Score™ of 17/100.

LakeShore Biopharma Co's cash flow for dividends for the six months ended in Mar. 2025 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

LakeShore Biopharma Co Cash Flow for Dividends Related Terms

LakeShore Biopharma Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Cash Flow for Dividends Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Cash Flow for Dividends
0.00 0.00 0.00 0.00 0.00

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:H6Z0
17GF Score
LakeShore Biopharma Co Ltd FRA:H6Z0
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LakeShore Biopharma Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
LakeShore Biopharma Co (FRA:H6Z0) has a Cash Flow for Dividends of €0.00 Mil as of Mar. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Cash Flow for Dividends too high?
LakeShore Biopharma Co's current Cash Flow for Dividends is €0.00 Mil. Overall, LakeShore Biopharma Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does LakeShore Biopharma Co's Cash Flow for Dividends compare to ACUT and PPCB?
LakeShore Biopharma Co's Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (FRA:H6Z0) has a current Cash Flow for Dividends of €0.00 Mil. The current Cash Flow for Dividends is €0.00 Mil. LakeShore Biopharma Co's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For LakeShore Biopharma Co (FRA:H6Z0), the current Cash Flow for Dividends is €0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Other Exchanges LSBCF:USA
Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
17GF Score

Get the complete analysis for FRA:H6Z0

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.67
Price